公开(公告)号：US5223271A

公开(公告)日：1993-06-29

申请号：US765008

申请日：1991-09-24

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K9/06 ,  A61K31/17 ,  A61K31/19 ,  A61K31/20 ,  A61K31/202 ,  A61K31/505 ,  A61K31/60 ,  A61K31/63 ,  A61K33/00 ,  A61K33/14 ,  A61K47/20 ,  A61P17/00 ,  A61P31/12 ,  A61P43/00 ,  C01D3/04 ,  C01D7/00 ,  C07C55/10 ,  C07C57/12 ,  C07D239/557

CPC classification number: A61K9/0014 ,  A61K31/19 ,  A61K31/20 ,  A61K31/505 ,  A61K31/60 ,  A61K31/63 ,  A61K33/00 ,  A61K33/14 ,  A61K47/20

Abstract: The present invention provides a method of treatment and/or prophylaxis of the human or animal body to combat Molluscum Contagiosum, said treatment comprising topically administering a therapeutically or prophylactically effective amount of a physiologically acceptable lithium compound to affected areas on said body.It also extends to pharmaceutical compositions comprising a physiologically acceptable lithium compound together with at least one keratolytic and/or skin penetration assisting agent and at least one pharmaceutically acceptable carrier or excipient.

公开(公告)号：US5128152A

公开(公告)日：1992-07-07

申请号：US711104

申请日：1991-06-03

Applicant: David F. Horrobin ,  Michel E. Begin

Inventor： David F. Horrobin ,  Michel E. Begin

IPC: A61K31/19 ,  A61K31/20 ,  A61K31/23 ,  A61K31/295 ,  A61K33/26 ,  A61P35/00

CPC classification number: A61K31/20 ,  A61K31/23 ,  A61K33/26

Abstract: Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.

Abstract translation: 一种或多种n-6或n-3必需脂肪酸，特别是γ-亚麻酸，二氢-γ-亚麻酸或二十碳五烯酸和可同化铁化合物的药学上可接受的组合物以剂量单位形式任选地含有稀释剂或载体 所述酸以本身的形式存在或作为在体内可转化为衍生物的衍生物，所述酸或衍生物的量为1mg至100g（以γ-亚麻酸计算）和所述铁化合物0.1mg至10g（以 铁）或所述量的次数便于日常给药。

公开(公告)号：US4965075A

公开(公告)日：1990-10-23

申请号：US273680

申请日：1988-11-21

Applicant: David F. Horrobin ,  Stephen C. Cunnane ,  Mehar S. Manku

Inventor： David F. Horrobin ,  Stephen C. Cunnane ,  Mehar S. Manku

IPC: A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/30 ,  A61K33/34 ,  A61P3/06 ,  A61P7/02 ,  A61P9/00 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/18 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00

CPC classification number: A61K31/20 ,  A61K33/34 ,  Y10S514/866

Abstract: Methods of influencing the 1-series/2-series PG balance in the body by administering a composition containing .gamma.-linolenic acid and/or dihomo-.gamma.-linolenic acid and assimilable copper compounds optionally with a diluent or carrier, the acids being as such or as derivatives convertible in the body thereto. The amounts of the acids or derivatives are 0.2 to 10 g (calculated as .gamma.-linolenic acid) and of copper compounds are 0.1 to 100 mg (calculated as copper).

Abstract translation: 通过施用含有γ-亚麻酸和/或二 - γ-亚麻酸的组合物和任选地与稀释剂或载体同化的铜化合物来影响体内1系/ 2系PG平衡的方法，酸如此 或作为在体内可转换的衍生物。 酸或衍生物的量为0.2〜10g（以γ-亚麻酸计算），铜化合物的量为0.1〜100mg（以铜计）。

公开(公告)号：US4758592A

公开(公告)日：1988-07-19

申请号：US911719

申请日：1986-09-26

Applicant: David F. Horrobin ,  Robert A. Casper

Inventor： David F. Horrobin ,  Robert A. Casper

IPC: A61K31/16 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61P43/00 ,  A61K31/22

CPC classification number: A61K31/16 ,  A61K31/20 ,  A61K31/23

Abstract: Method of prevention or treatment of endometriosis wherein effective amounts of one or both of (i) gamma-linolenic acid and/or dihomo-gamma-linolenic acid and (ii) 18:4 n-3 and/or one or more of the metabolites of 18:4 n-3 (20:4 n-3, 20:5 n-3, 22:5 n-3 or 22:6 n-3) are administered against endometriosis as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto, alone or in an acceptable pharmaceutical carrier or diluent.

Abstract translation: 预防或治疗子宫内膜异位症的方法，其中有效量的（i）γ-亚麻酸和/或二 - γ-亚麻酸和（ii）18：4n-3和/或一种或多种代谢物中的一种或两种 18：4 n-3（20：4 n-3,20：5 n-3,22：5 n-3或22：6 n-3）与子宫内膜异位症一起施用或以酯的形式施用， 盐，酰胺或其它可衍生于体内的衍生物，单独或在可接受的药物载体或稀释剂中。

公开(公告)号：US4666701A

公开(公告)日：1987-05-19

申请号：US839228

申请日：1986-03-13

Applicant: David F. Horrobin ,  Mehar S. Manku ,  Yung S. Huang

Inventor： David F. Horrobin ,  Mehar S. Manku ,  Yung S. Huang

IPC: A61K31/00 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61P1/00 ,  A61P1/04 ,  A61P29/00 ,  A61K27/00

CPC classification number: A61K31/20 ,  A61K31/23 ,  Y10S514/922

Abstract: Gamma-linolenic acid or dihomo-gamma-linolenic acid for use in the reduction or prevention of gastro-intestinal bleeding and other side effects shown by NSAIDs when administered on a continuing basis, including use in allowing said administration to be replaced by administration of said acid alone in arthritis and other conditions without exacerbation of symptoms.

Abstract translation: 用于减少或预防胃肠道出血的γ-亚麻酸或二 - 亚麻酸，以及NSAIDs持续施用时所显示的其它副作用，包括用于允许所述给药被施用所述 酸单独在关节炎等条件下无症状加重。

公开(公告)号：US4328243A

公开(公告)日：1982-05-04

申请号：US251901

申请日：1981-04-07

Applicant: David F. Horrobin ,  Julian Lieb

Inventor： David F. Horrobin ,  Julian Lieb

IPC: A61K31/20 ,  A61K33/00 ,  C07C57/03

CPC classification number: C07C57/03 ,  A61K31/20 ,  A61K33/00

Abstract: A method for the treatment and/or prophylaxis of the side-effects of lithium treatment in a subject suffering from manic-depressive psychosis, which method comprises administering to the subject an effective amount therefor of dihomogamma-linolenic acid and/or a biosynthetic precursor thereof.

Abstract translation: 一种用于治疗和/或预防患有躁狂抑郁精神病的受试者的锂处理的副作用的方法，该方法包括向受试者施用有效量的二羟基亚麻酸和/或其生物合成前体 。

公开(公告)号：US5763484A

公开(公告)日：1998-06-09

申请号：US823790

申请日：1997-03-24

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A23D9/00 ,  A23L1/30 ,  A23L1/325 ,  A23L1/48 ,  A61K31/16 ,  A61K31/20 ,  A61K31/22 ,  A61K31/23 ,  A61K31/557 ,  A61K35/56 ,  A61K35/60 ,  A61K36/00 ,  A61K36/185 ,  A61K38/00 ,  A61P3/08 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/30 ,  A61P27/16 ,  A61P35/00 ,  A61P37/08

CPC classification number: A61K35/60 ,  A23D9/00 ,  A61K31/20 ,  A61K31/23 ,  A61K31/557 ,  A61K36/185 ,  Y10S514/861 ,  Y10S514/866

Abstract: A method of treatment of a disorder, including breast cancer and other cancer, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-y or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in acceptable pharmaceutical carrier or diluent.

Abstract translation: 一种治疗包括乳腺癌和其他癌症的病症的方法，其有效量的一种或多种亚油酸代谢物（GLA，DGLA，AA，22：4n-y或22：5n-6）和一种或多种 更多的如此给予的α-亚麻酸（18：4n-3,20：4n-3,20：5n-3,22：5n-3或22：6n-3）的代谢物或酯的形式 ，盐，酰胺或其它可在体内转化为其的衍生物，或在可接受的药物载体或稀释剂中。

公开(公告)号：US5614208A

公开(公告)日：1997-03-25

申请号：US600004

申请日：1996-02-14

Applicant: David F. Horrobin ,  Yung-Sheng Huang

Inventor： David F. Horrobin ,  Yung-Sheng Huang

IPC: A61K31/23 ,  A23D9/00 ,  A23L1/30 ,  A61K8/00 ,  A61K8/30 ,  A61K8/37 ,  A61K8/96 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P25/04 ,  A61Q5/00 ,  A61Q19/00 ,  C07C69/587 ,  C11B3/10 ,  C11B7/00 ,  C11D3/06 ,  A61K9/70 ,  A61K9/14 ,  A61K31/20 ,  A61K47/12

CPC classification number: A23D9/00 ,  A61K31/23 ,  C07C69/587

Abstract: Atopic eczema, breast pain or premenstrual syndrome are treated by administering to a person in need of same a composition containing at least 20% di-linoleoyl-mono-gamma-linolenyl glycerol by weight.

Abstract translation: 特应性湿疹，乳房疼痛或经前期综合征通过给予需要相同组合物的人治疗，所述组合物含有至少20％重量的二亚油酰基单一γ-亚麻醇甘油。

公开(公告)号：US5552150A

公开(公告)日：1996-09-03

申请号：US158986

申请日：1993-11-30

Applicant: David F. Horrobin ,  Yung-Sheng Huang

Inventor： David F. Horrobin ,  Yung-Sheng Huang

IPC: A61K31/23 ,  A23D9/00 ,  A23L1/30 ,  A61K8/00 ,  A61K8/30 ,  A61K8/37 ,  A61K8/96 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P25/04 ,  A61Q5/00 ,  A61Q19/00 ,  C07C69/587 ,  C11B3/10 ,  C11B7/00 ,  C11D3/06 ,  A61K31/20 ,  A61K9/14 ,  A61K47/12

CPC classification number: A23D9/00 ,  A61K31/23 ,  C07C69/587

Abstract: A natural or synthetic glycerol oil which comprises at least 20% by weight, preferably at least 25% of di-linoleoyl-mono-gamma-linolenyl-glycerol (DLMG), is used to supplement foods, nutritional compositions and in skin and hair care compositions.

Abstract translation: 使用包含至少20重量％，优选至少25％的二亚油酰 - 单γ-亚麻油烯甘油（DLMG）的天然或合成甘油油来补充食物，营养组合物和皮肤和头发护理 组合物。

公开(公告)号：US5324748A

公开(公告)日：1994-06-28

申请号：US956460

申请日：1992-10-02

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/23 ,  A61K38/21 ,  A61K45/06 ,  A61K31/015 ,  A61K31/07

CPC classification number: A61K38/21 ,  A61K31/20 ,  A61K31/23 ,  A61K45/06

Abstract: A composition of an effective amount of (a) .gamma.-linolenic acid and/or dihomo-.gamma.-linolenic acid, optionally in association with linoleic and if desired other fat acids, said acids being used if desired as physiologically functional derivatives thereof, in conjunction with (b) an effective amount of one or more of natural or synthetic carotenoids or retinoids having, or giving rise in the body to compounds having, Vitamin A activity when used in therapy of a condition in which enhancement of 1-series PG production, or more broadly influence of the 1-series/2-series PG balance in the body in favor of 1-series PGs is required.

Abstract translation: 有效量的（a）γ-亚麻酸和/或二 - γ-亚麻酸的组合物，任选地与亚油酸和任何其它脂肪酸一起使用，如果需要，所述酸作为其生理功能衍生物，结合使用 与（b）有效量的一种或多种天然或合成类胡萝卜素或类视黄醇，当用于治疗1系PG生产增强的病症时，具有或引起体内具有维生素A活性的化合物， 或更广泛地影响1系列/ 2系PG平衡在体内有利于1系列PGs。